Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen

• Published in: AIDS (London) Vol. 21; no. 2; pp. 268 - 269
• Main Authors: Pavel, Simona, Burty, Christine, Alcaraz, Isabelle, de la Tribonnière, Xavier, Baclet, Véronique, Ajana, Faiza, Mouton, Yves, Rabaud, Christian, Yazdanpanah, Yazdan
• Format: Journal Article
• Language: English
• Published: England 11-01-2007
• Subjects: Adult; Anti-HIV Agents - adverse effects; Antiretroviral Therapy, Highly Active - adverse effects; Chemical and Drug Induced Liver Injury - etiology; Female; HIV Infections - prevention & control; Human immunodeficiency virus; Humans; Male; France
• ISSN: 0269-9370
• DOI: 10.1097/QAD.0b013e328011aa35

In France, post-exposure prophylaxis (PEP) is provided to patients after HIV occupational or sexual exposure. Current guidelines recommend the use of combined antiretroviral therapy (i.e. two nucleoside reverse-transcriptase inhibitors and one protease inhibitor) for 4 weeks. After January, 2006, in the Infectious Disease Department of Lille University at Tourcoing Hospital, France, in the absence of genotypic resistance mutations to antiretroviral drugs in source patients, PEP provided to patients exposed to HIV was changed from zidovudine/ lamivudine (combivir) 300mg/150mg twice a day, and nelfinavir (1250 mg twice a day) to combivir and fosamprenavir/ritonavir (700/100 mg twice a day).